Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern

Microbial Pathogenesis

Volumn 100, Issue , 2016, Pages 201-204

  Mazloomi Nobandegani, Narges ^a   Mahmoudi, Shima ^b   Pourakbari, Babak ^b   Hosseinpour Sadeghi, Reihaneh ^b   Najafi Sani, Mehri ^a   Farahmand, Fateme ^a   Motamed, Farzaneh ^a   Nabavizadeh Rafsanjani, Raheleh ^a   Mamishi, Setareh ^a,b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cystic fibrosis; Methicillin resistant S. aureus; P. aeruginosa

Indexed keywords

AMIKACIN; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIFAMOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METICILLIN; MINOCYCLINE; MOXIFLOXACIN; PENICILLIN G; POLYMYXIN B; PSEUDOMONIC ACID; RIFAMPICIN; TETRACYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BURKHOLDERIA CEPACIA COMPLEX; CHILD; CYSTIC FIBROSIS; FEMALE; HUMAN; INFANT; IRANIAN PEOPLE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; PEDIATRIC HOSPITAL; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM CULTURE; STAPHYLOCOCCUS AUREUS; BACTERIAL INFECTIONS; COMPLICATION; DRUG EFFECTS; IRAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PRESCHOOL CHILD; SPUTUM;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BURKHOLDERIA CEPACIA COMPLEX; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFANT; IRAN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PSEUDOMONAS AERUGINOSA; SPUTUM;

EID: 84989344911     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2016.09.015     Document Type: Article

References (35)

1. [1] French, G.L., The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents 36:Suppl. 3 (2010), S3–S7.
2. [2] Valenza, G., Tappe, D., Turnwald, D., Frosch, M., Konig, C., Hebestreit, H., et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 7:2 (2008), 123–127.
3. [3] Nadesalingam, K., Conway, S.P., Denton, M., Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J. Cyst. Fibros. 4:1 (2005), 49–52.
4. [4] Sabouni, F., Ranjbari, R., Pourakbari, B., Mahmoudi, S., Teymuri, M., Ashtiani, M.T., et al. Staphylococcus aureus infections in children in an Iranian referral pediatric hospital. J. Prev. Med. Hyg. 54:4 (2013), 205–207.
5. [5] Saiman, L., Siegel, J., Infection control in cystic fibrosis. Clin. Microbiol. Rev. 17:1 (2004), 57–71.
6. [6] Rajan, S., Saiman, L., Pulmonary infections in patients with cystic fibrosis. Semin. Respir. Infect. 17:1 (2002), 47–56.
7. [7] Hauser, A.R., Jain, M., Bar-Meir, M., McColley, S.A., Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24:1 (2011), 29–70.
8. [8] Mearns, M.B., Hunt, G.H., Rushworth, R., Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-71. Arch. Dis. Child. 47:256 (1972), 902–907.
9. [9] Goss, C.H., Muhlebach, M.S., Review: Staphylococcus aureus and MRSA in cystic fibrosis. J. Cyst. Fibros. 10:5 (2011), 298–306.
10. [10] Dasenbrook, E.C., Merlo, C.A., Diener-West, M., Lechtzin, N., Boyle, M.P., Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am. J. Respir. Crit. Care Med. 178:8 (2008), 814–821.
11. [11] Sanders, D.B., Bittner, R.C., Rosenfeld, M., Hoffman, L.R., Redding, G.J., Goss, C.H., Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 182:5 (2010), 627–632.
12. [12] Dasenbrook, E.C., Checkley, W., Merlo, C.A., Konstan, M.W., Lechtzin, N., Boyle, M.P., Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. Jama 303:23 (2010), 2386–2392.
13. [13] Fusco, N.M., Toussaint, K.A., Prescott, W.A., Antibiotic management of methicillin-resistant Staphylococcus aureus–associated acute pulmonary exacerbations in cystic fibrosis. Ann. Pharmacother. 49:4 (2015), 458–468.
14. [14] Wikler, M.A., Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. 2009, Clinical and Laboratory Standards Institute.
15. [15] Ghazi, M., Khanbabaee, G., Fallah, F., Kazemi, B., Mahmoudi, S., Navidnia, M., et al. Emergence of Pseudomonas aeruginosa cross-infection in children with cystic fibrosis attending an Iranian referral pediatric center. Iran. J. Microbiol. 4:3 (2012), 124–129.
16. [16] Anzaudo, M.M., Busquets, N.P., Ronchi, S., Mayoral, C., Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis. Rev. Argent. Microbiol. 37:3 (2005), 129–134.
17. [17] Semczuk, K., Dmenska, H., Dzierzanowska, D., Kolodziejczyk, M., Gabinska, E., Zareba, H., The analysis of the isolated microorganisms from the respiratory tract of cystic fibrosis patients treated in Children's Memorial Health Institute 1999-2002. Pneumonol. Alergol. Pol. 73:1 (2005), 41–47.
18. [18] Garcia, A.D., Ibarra, A., Rodriguez, F.C., Casal, M., Antimicrobial susceptibility of bacterial isolates from patients with cystic fibrosis. Rev. Esp. Quimioter. 17:4 (2004), 332–335.
19. [19] Burns, J.L., Emerson, J., Stapp, J.R., Yim, D.L., Krzewinski, J., Louden, L., et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin. Infect. Dis. 27:1 (1998), 158–163.
20. [20] Ratjen, F., Comes, G., Paul, K., Posselt, H.G., Wagner, T.O., Harms, K., Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis. Pediatr. Pulmonol. 31:1 (2001), 13–16.
21. [21] Pritt, B., O'Brien, L., Winn, W., Mucoid Pseudomonas in cystic fibrosis. Am. J. Clin. Pathol. 128:1 (2007), 32–34.
22. [22] Vidya, P., Smith, L., Beaudoin, T., Yau, Y.C., Clark, S., Coburn, B., et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol. 35:1 (2016), 67–74.
23. [23] Duong, J., Booth, S.C., McCartney, N.K., Rabin, H.R., Parkins, M.D., Storey, D.G., Phenotypic and genotypic comparison of epidemic and non-epidemic strains of Pseudomonas aeruginosa from individuals with cystic fibrosis. PloS One, 10(11), 2015, e0143466.
24. [24] Fazeli, H., Akbari, R., Moghim, S., Esfahani, B.N., Phenotypic characterization and PCR-Ribotypic profile of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Iran. Adv. Biomed. Res., 2, 2013, 18.
25. [25] Owlia, P., Nosrati, R., Alaghehbandan, R., Lari, A.R., Antimicrobial susceptibility differences among mucoid and non-mucoid Pseudomonas aeruginosa isolates. GMS Hyg. Infect. Control, 9(2), 2014 Doc13.
26. [26] Lynch, J.P. 3rd, Burkholderia cepacia complex: impact on the cystic fibrosis lung lesion. Semin. Respir. Crit. Care Med. 30:5 (2009), 596–610.
27. [27] Zemanick, E.T., Emerson, J., Thompson, V., McNamara, S., Morgan, W., Gibson, R.L., et al. Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. Pediatr. Pulmonol. 50:1 (2015), 42–48.
28. [28] Kerem, E., Reisman, J., Corey, M., Canny, G.J., Levison, H., Prediction of mortality in patients with cystic fibrosis. N. Engl. J. Med. 326:18 (1992), 1187–1191.
29. [29] Razvi, S., Quittell, L., Sewall, A., Quinton, H., Marshall, B., Saiman, L., Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:6 (2009), 1554–1560.
30. [30] Mamishi, S., Mahmoudi, S., Sadeghi, R.H., Movahedi, Z., Hadipour, R., Pourakbari, B., Genotyping of Staphylococcus aureus strains among healthcare workers and patients in the tertiary referral Children's Medical Hospital in Tehran, Iran. Br. J. Biomed. Sci. 69:4 (2012), 173–177.
31. [31] Sabouni, F., Mahmoudi, S., Bahador, A., Pourakbari, B., Sadeghi, R.H., Ashtiani, M.T., et al. Virulence factors of Staphylococcus aureus isolates in an Iranian referral children's hospital. Osong Public Health Res. Perspect. 5:2 (2014), 96–100.
32. [32] Pourakbari, B., Sadr, A., Ashtiani, M.T.H., Mamishi, S., Dehghani, M., Mahmoudi, S., et al. Five-year evaluation of the antimicrobial susceptibility patterns of bacteria causing bloodstream infections in Iran. J. Infect. Dev. Ctries. 6:02 (2011), 120–125.
33. [33] Mamishi, S., Pourakbari, B., Ashtiani, M.H., Hashemi, F.B., Frequency of isolation and antimicrobial susceptibility of bacteria isolated from bloodstream infections at Children's Medical Center, Tehran, Iran, 1996–2000. Int. J. Antimicrob. Agents 26:5 (2005), 373–379.
34. [34] Mamishi, S., Mahmoudi, S., Bahador, A., Matini, H., Movahedi, Z., Sadeghi, R.H., et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in an Iranian referral paediatric hospital. Br. J. Biomed. Sci. 72:2 (2015), 47–51.
35. [35] Dasenbrook, E.C., Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Curr. Opin. Pulm. Med. 17:6 (2011), 437–441.